A Study of Olomorasib (LY3537982) in Healthy Participants
A Phase 1, Open-Label, Fixed-Sequence Study to Investigate the Effect of Fluconazole on the Pharmacokinetics of Olomorasib (LY3537982) in Healthy Participants
Sponsor: Eli Lilly and Company
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Olomorasib
Time frame: Baseline, Day 12
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olomorasib
Time frame: Baseline, Day 12
Eligibility Criteria
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Must have a Body Mass Index (BMI) within the range of 18.0 to 30.0 kilograms per square meter (kg/m2) * Participants assigned male at birth (AMAB) or participants assigned female at birth (AFAB) who are individuals not of childbearing potential (INOCBP). Exclusion Criteria: * History or presence of the following conditions: * metabolic disease * biliary disease * gastrointestinal disease * hematological disease * neurological disease * significant history of hepatic disease * clinically significant, active cardiovascular disease or history of myocardial infarction within 6 months prior to Day 1 * Abnormal blood pressure or pulse rate * Have a 12-lead electrocardiogram (ECG) abnormality, in the opinion of the investigator, increases the risks associated with participating in the study, or may confound…
Read full criteria on CT.gov →✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →